---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-255878"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-10-13T23:59:59+00:00"
generated_at: "2026-06-10T00:02:31.542443+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines reports positive clinical data for RMC-6236 and RMC-6291; selects RMC-5127

## Summary
- RMC-6236 shows acceptable safety in 131 patients; common TRAEs include rash (70%) and GI toxicities, mostly Grade 1-2.
- RMC-6236 demonstrates dose-dependent exposure and ctDNA reductions across NSCLC, PDAC, and multiple KRAS mutations.
- RMC-6291 achieves 50% ORR in NSCLC (prior G12Ci) and 43% in G12Ci-naïve; 40% ORR in CRC with 80% DCR.
- RMC-6291 safety includes 25% QTc prolongation (11% Grade 3) but no cardiac sequelae or hepatotoxicity signal.
- RMC-5127, an oral covalent tri-complex inhibitor of KRAS G12V (ON), selected as a development candidate.

## SEC filing metadata
- accession: 0001193125-23-255878
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-10-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312523255878/0001193125-23-255878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312523255878/d566894d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-255878
- JSON: https://secwatch.observer/filing/0001193125-23-255878.json
- Plain text: https://secwatch.observer/filing/0001193125-23-255878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.